Breakthrough in Oncology: Introducing Sacituzumab Govitecan and Brentuximab Vedotin
Introduction
In the ever-evolving landscape of oncology, the advent of targeted therapies continues to offer hope for patients facing various forms of cancer. Two such innovative treatments, Sacituzumab govitecan and Brentuximab vedotin, have emerged as potent options, especially in the combat against hard-to-treat cancers. Both are antibody-drug conjugates (ADCs) that blend the specificity of...